Annual direct medical cost and contributing factors to total cost of epilepsy in Oman

Ibrahim Al-Zakwani, Yolande Hanssens, Dirk Deleu, Abigail Cohen, William McGhan, Khalid Al-Balushi, Amna Al-Hashar

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objectives: To describe the pharmaceutical use, health care resource utilisation patterns, and annual direct medical cost of epilepsy as well as determining the impact of various demographic and clinical characteristics on total costs of epilepsy in Oman. Methods: Medical and pharmacy data were collected for 6 months on all patients aged ≥ 13 years attending the Sultan Qaboos University Hospital. Unit pharmacy and medical costs were retrieved for each patient, and multiple linear regression was utilised to analyse the impact of various demographic and clinical characteristics on total cost. Results: A total of 486 patients were seen over the study period. Annual direct medical costs of epilepsy amounted to US$1426. In-patient care, the antiepileptic drug (AED) lamotrigine and specialist visits, respectively, were the first, second and third most significant predictors of total cost. Age was associated positively, and was the most significant predictor of total costs among demographic and clinical parameters. Conclusions: This analysis, the first economic study of epilepsy in Oman, could assist in health care allocation of scarce resources and in pharmacoeconomic analysis of AEDs. Besides in-patient admission, our findings demonstrate that the newer drugs are significant predictors of total cost, and hence any incremental benefits derived from them must be rigorously assessed for their cost-effectiveness.

Original languageEnglish
Pages (from-to)555-560
Number of pages6
JournalSeizure
Volume12
Issue number8
DOIs
Publication statusPublished - Dec 2003

Fingerprint

Oman
Epilepsy
Costs and Cost Analysis
Demography
Patient Acceptance of Health Care
Pharmaceutical Economics
Resource Allocation
Health Resources
Patient Admission
Pharmaceutical Preparations
Anticonvulsants
Cost-Benefit Analysis
Linear Models
Patient Care
Economics
Delivery of Health Care

Keywords

  • Antiepileptic drugs
  • Cost
  • Direct cost
  • Epilepsy
  • Oman

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Psychology(all)

Cite this

Annual direct medical cost and contributing factors to total cost of epilepsy in Oman. / Al-Zakwani, Ibrahim; Hanssens, Yolande; Deleu, Dirk; Cohen, Abigail; McGhan, William; Al-Balushi, Khalid; Al-Hashar, Amna.

In: Seizure, Vol. 12, No. 8, 12.2003, p. 555-560.

Research output: Contribution to journalArticle

Al-Zakwani, Ibrahim ; Hanssens, Yolande ; Deleu, Dirk ; Cohen, Abigail ; McGhan, William ; Al-Balushi, Khalid ; Al-Hashar, Amna. / Annual direct medical cost and contributing factors to total cost of epilepsy in Oman. In: Seizure. 2003 ; Vol. 12, No. 8. pp. 555-560.
@article{8cb415af30af46499cced1a7fbe5bbc8,
title = "Annual direct medical cost and contributing factors to total cost of epilepsy in Oman",
abstract = "Objectives: To describe the pharmaceutical use, health care resource utilisation patterns, and annual direct medical cost of epilepsy as well as determining the impact of various demographic and clinical characteristics on total costs of epilepsy in Oman. Methods: Medical and pharmacy data were collected for 6 months on all patients aged ≥ 13 years attending the Sultan Qaboos University Hospital. Unit pharmacy and medical costs were retrieved for each patient, and multiple linear regression was utilised to analyse the impact of various demographic and clinical characteristics on total cost. Results: A total of 486 patients were seen over the study period. Annual direct medical costs of epilepsy amounted to US$1426. In-patient care, the antiepileptic drug (AED) lamotrigine and specialist visits, respectively, were the first, second and third most significant predictors of total cost. Age was associated positively, and was the most significant predictor of total costs among demographic and clinical parameters. Conclusions: This analysis, the first economic study of epilepsy in Oman, could assist in health care allocation of scarce resources and in pharmacoeconomic analysis of AEDs. Besides in-patient admission, our findings demonstrate that the newer drugs are significant predictors of total cost, and hence any incremental benefits derived from them must be rigorously assessed for their cost-effectiveness.",
keywords = "Antiepileptic drugs, Cost, Direct cost, Epilepsy, Oman",
author = "Ibrahim Al-Zakwani and Yolande Hanssens and Dirk Deleu and Abigail Cohen and William McGhan and Khalid Al-Balushi and Amna Al-Hashar",
year = "2003",
month = "12",
doi = "10.1016/S1059-1311(03)00068-2",
language = "English",
volume = "12",
pages = "555--560",
journal = "Seizure : the journal of the British Epilepsy Association",
issn = "1059-1311",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Annual direct medical cost and contributing factors to total cost of epilepsy in Oman

AU - Al-Zakwani, Ibrahim

AU - Hanssens, Yolande

AU - Deleu, Dirk

AU - Cohen, Abigail

AU - McGhan, William

AU - Al-Balushi, Khalid

AU - Al-Hashar, Amna

PY - 2003/12

Y1 - 2003/12

N2 - Objectives: To describe the pharmaceutical use, health care resource utilisation patterns, and annual direct medical cost of epilepsy as well as determining the impact of various demographic and clinical characteristics on total costs of epilepsy in Oman. Methods: Medical and pharmacy data were collected for 6 months on all patients aged ≥ 13 years attending the Sultan Qaboos University Hospital. Unit pharmacy and medical costs were retrieved for each patient, and multiple linear regression was utilised to analyse the impact of various demographic and clinical characteristics on total cost. Results: A total of 486 patients were seen over the study period. Annual direct medical costs of epilepsy amounted to US$1426. In-patient care, the antiepileptic drug (AED) lamotrigine and specialist visits, respectively, were the first, second and third most significant predictors of total cost. Age was associated positively, and was the most significant predictor of total costs among demographic and clinical parameters. Conclusions: This analysis, the first economic study of epilepsy in Oman, could assist in health care allocation of scarce resources and in pharmacoeconomic analysis of AEDs. Besides in-patient admission, our findings demonstrate that the newer drugs are significant predictors of total cost, and hence any incremental benefits derived from them must be rigorously assessed for their cost-effectiveness.

AB - Objectives: To describe the pharmaceutical use, health care resource utilisation patterns, and annual direct medical cost of epilepsy as well as determining the impact of various demographic and clinical characteristics on total costs of epilepsy in Oman. Methods: Medical and pharmacy data were collected for 6 months on all patients aged ≥ 13 years attending the Sultan Qaboos University Hospital. Unit pharmacy and medical costs were retrieved for each patient, and multiple linear regression was utilised to analyse the impact of various demographic and clinical characteristics on total cost. Results: A total of 486 patients were seen over the study period. Annual direct medical costs of epilepsy amounted to US$1426. In-patient care, the antiepileptic drug (AED) lamotrigine and specialist visits, respectively, were the first, second and third most significant predictors of total cost. Age was associated positively, and was the most significant predictor of total costs among demographic and clinical parameters. Conclusions: This analysis, the first economic study of epilepsy in Oman, could assist in health care allocation of scarce resources and in pharmacoeconomic analysis of AEDs. Besides in-patient admission, our findings demonstrate that the newer drugs are significant predictors of total cost, and hence any incremental benefits derived from them must be rigorously assessed for their cost-effectiveness.

KW - Antiepileptic drugs

KW - Cost

KW - Direct cost

KW - Epilepsy

KW - Oman

UR - http://www.scopus.com/inward/record.url?scp=0344668629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344668629&partnerID=8YFLogxK

U2 - 10.1016/S1059-1311(03)00068-2

DO - 10.1016/S1059-1311(03)00068-2

M3 - Article

C2 - 14630493

AN - SCOPUS:0344668629

VL - 12

SP - 555

EP - 560

JO - Seizure : the journal of the British Epilepsy Association

JF - Seizure : the journal of the British Epilepsy Association

SN - 1059-1311

IS - 8

ER -